{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The local failure rate will be estimated using cumulative incidence curves for Group III patients who received reduced doses of radiation therapy after second look surgical resection.","groups":[{"description":"Stage I group III nonorbit primary or stage III group I/II patients receive VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 10; VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); and radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose. Some patients do not receive radiation therapy; some start it at week 24. (closed to accrual as of 08/13/2010)\n\ndactinomycin: Given IV\n\ncyclophosphamide: Given IV\n\nvincristine sulfate: Given IV\n\nradiation therapy: Undergo radiotherapy","id":"OG000","title":"Regimen II (Stage I Group III Nonorbit or Stage III Group I/II"}],"paramType":"NUMBER","populationDescription":"Patients with Group III vaginal primary tumor","reportingStatus":"POSTED","timeFrame":"From enrollment up to 20 weeks","title":"Cumulative Incidence of Group III Patients Who Received With Reduced Radiotherapy Dose","type":"SECONDARY","unitOfMeasure":"Estimated percentage of participants"}